[8-K] Benitec Biopharma Inc. Reports Material Event

Rhea-AI Filing Summary

OneStream, Inc. (OS) Form 4 filing: Director Jonathan D. Mariner sold 6,630 Class A common shares on 07/07/2025 at a weighted-average price of $26.59 under a Rule 10b5-1 trading plan adopted on 02/28/2025. After the sale, Mariner still beneficially owns 40,280 shares, which include unvested restricted stock units. No derivative transactions were reported.

The transaction reduces Mariner’s direct holdings by roughly 14% but maintains a sizable position, suggesting portfolio rebalancing rather than a full exit. The use of a pre-arranged plan limits the signaling effect because it indicates the sale was scheduled in advance and not driven by new, undisclosed information.

Positive

• Sale executed under a Rule 10b5-1 plan, indicating pre-planned disposition and reducing concerns about opportunistic trading.

Negative

• Director reduced direct ownership by 6,630 shares (≈14%), which can be interpreted as a modestly bearish insider signal.

Insights

Securities Analyst

TL;DR: Director sells 6,630 shares (~$176k) via 10b5-1; modestly negative sentiment.

The filing shows a single, routine sale representing about 14% of the director’s stake, leaving over 40k shares outstanding. Because the transaction occurred under a 10b5-1 plan, the informational value is muted; however, insider selling—particularly by a board member—generally skews slightly bearish for near-term sentiment. The remaining stake and continued board role temper concerns. Overall impact on valuation is minimal, but traders may view the activity as a short-term supply overhang.

false 0001808898 0001808898 2025-07-09 2025-07-09

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 9, 2025

BENITEC BIOPHARMA INC.

(Exact name of registrant as specified in its charter)

Delaware		001-39267		84-4620206
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)
3940 Trust Way, Hayward, California				94545
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (510) 780-0819

(Former Name or Former Address, if Changed Since Last Report): Not Applicable

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001		BNTC		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On July 9, 2025, Benitec Biopharma Inc. (the “Company”) issued a press release providing an update that the sixth and final Subject of Cohort 1 was safely treated with the Low Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study (NCT06185673), the Data Safety Monitoring Board recommended the continuation of Subject enrollment for the Phase 1b/2a Clinical Treatment Study and that the enrollment of Cohort 2 is expected to begin in the fourth calendar quarter of 2025. A copy of the press release, which is attached hereto as Exhibit 99.1, is furnished pursuant to this Item 7.01.

The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be incorporated by reference into any filing of the Company, whether made before, on or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference to such filing. The information contained in Item 7.01 of this Current Report on Form 8-K Report, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

				BENITEC BIOPHARMA INC.
Date: July 9, 2025						/s/ Jerel A. Banks
				Name:		Jerel A. Banks
				Title:		Chief Executive Officer

FAQ

How many OneStream (OS) shares did Director Jonathan D. Mariner sell?

He sold 6,630 Class A common shares on 07/07/2025.

What price did the OS shares sell for?

The weighted-average sale price was $26.59 per share, within a range of $26.35–$26.76.

Does Mariner still hold OneStream stock after the sale?

Yes. He beneficially owns 40,280 shares, including unvested restricted stock units.

Was the sale part of a Rule 10b5-1 trading plan?

Yes. The plan was adopted on 02/28/2025, indicating the sale was pre-arranged.

Is any derivative security activity disclosed in this Form 4?

No. The filing reports no derivative transactions for the period.